Affinity Asset Advisors

ProMIS Neurosciences is a development-stage biotechnology company focused on discovering and developing precision therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, primarily Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS). Incorporated in 2004, the company is headquartered in Toronto, Canada.

Ceptur Therapeutics is focused on developing innovative genetic medicines for patients with unmet medical needs. The company utilizes its proprietary U1 Adaptor technology to achieve non-genotoxic, long-lasting silencing of disease-causing genes, particularly in challenging tissues beyond the liver and central nervous system. This technology addresses the limitations of existing gene silencing methods and has potential applications in cancer treatment, allowing healthcare providers to offer new therapeutic options for various cancer types. Through its advancements, Ceptur aims to improve patient outcomes by providing effective solutions for difficult-to-treat conditions.

Renovacor, Inc., established in 2013 and headquartered in Philadelphia, Pennsylvania, is a biopharmaceutical company dedicated to developing transformative gene therapies for cardiovascular diseases. Currently in the preclinical stage, Renovacor's primary focus is on creating a recombinant adeno-associated virus (AAV)-based gene therapy targeting patients with dilated cardiomyopathy (DCM) caused by mutations in the Bcl2-associated athanogene 3 (BAG3) gene. This condition affects approximately 35,000 individuals in the United States and Europe, qualifying it as an orphan disease. Renovacor aims to improve patient outcomes by potentially preventing disease progression through a BAG3 gene replacement therapy, given the current five-year survival rate of only 50% for DCM patients despite standard care.

Kurome Therapeutics, Inc. is a preclinical stage biotechnology company based in Cincinnati, Ohio, focused on developing innovative therapies for cancer treatment. Founded in 2019, the company specializes in targeting cancer cells that have hijacked immune signaling pathways to evade destruction by conventional therapies. By developing inhibitors that specifically address over-activated IRAK1/4-mediated signaling pathways, Kurome Therapeutics aims to disrupt the mechanisms that allow cancer cells to survive and resist treatment. Its approach is particularly relevant for hematological cancers, as it seeks to enhance the effectiveness of existing therapies and improve patient outcomes.

Identifeye is creating prediction models that combine multiple retinal imaging modalities with expert annotations to create comprehensive and non-invasive health assessments. Identifeye Health is a part of the 4Catalyzer accelerator, which is dedicated to improving patient care globally. It has offices in Guilford, Connecticut, New York City, and Palo Alto, California.

Ceptur Therapeutics is focused on developing innovative genetic medicines for patients with unmet medical needs. The company utilizes its proprietary U1 Adaptor technology to achieve non-genotoxic, long-lasting silencing of disease-causing genes, particularly in challenging tissues beyond the liver and central nervous system. This technology addresses the limitations of existing gene silencing methods and has potential applications in cancer treatment, allowing healthcare providers to offer new therapeutic options for various cancer types. Through its advancements, Ceptur aims to improve patient outcomes by providing effective solutions for difficult-to-treat conditions.

Lexeo Therapeutics is a fully integrated biotechnology company focused on developing adeno-associated virus (AAV)-mediated gene therapies. Its lead programs target both rare and non-rare monogenic diseases, with a preclinical pipeline that spans monogenic, hereditary, and acquired conditions across populations with unmet medical need. The company aims to advance clinical programs toward commercialization while maintaining an ongoing research collaboration with Weill Cornell Medicine’s Department of Genetic Medicine to inform and accelerate its preclinical and clinical work. By leveraging AAV-based approaches and collaborations, Lexeo Therapeutics seeks to transform treatment options for patients with genetic and complex diseases.